Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241285 | 0.86 | MAOA (0.41) | MAOAMAOBMAPKAPK2ATM | |
| SCHEMBL11026078 | 0.78 | MAOA (0.43) | MAOAMAOBMAPKAPK2ATMNPC1 | |
| SCHEMBL15287968 | 0.76 | MAOA (0.44) | MAOAMAOBMAPKAPK2ATMNPC1 | |
| SCHEMBL28471700 | 0.75 | MAPKAPK2 (0.48) | MAOAMAOBMAPKAPK2ATMNPC1 | |
| SCHEMBL7509523 | 0.73 | MAOA (0.44) | MAOAMAOBMAPKAPK2ATMNPC1 | |
| SCHEMBL29527796 | 0.72 | MAOA (0.59) | MAOAMAOBMAPKAPK2ATMACHE | |
| SCHEMBL3257951 | 0.72 | MAOA (0.59) | MAOAMAOBMAPKAPK2ATMACHE | |
| SCHEMBL11127249 | 0.71 | MAOA (0.53) | MAOAMAOBMAPKAPK2NPC1LMNA | |
| Hydrochloric Acid SCHEMBL29092000 | 0.71 | MAOA (0.57) | MAOAMAOBMAPKAPK2ATMACHE | |
| SCHEMBL5705630 | 0.70 | MAOA (0.41) | MAOAMAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4734896-A2 | BIOPOLYMER-BASED TYMPANOSTOMY TUBES WITH PROGRAMMABLE, TUNABLE, AND ON-DEMAND DEGRADATION | Trustees Of Tufts College (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735018-A2 | CENTRIFUGALLY-MOLDED ARTICLES AND METHODS | Trustees Of Tufts College (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260109671-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2025227091-A1 | IMPROVED WHIPPED SILK CREAMS AND METHODS OF MAKING AND USING THE SAME | TRUSTEES OF TUFTS COLLEGE (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12448352-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025091012-A1 | IMPROVED SILK LEATHER AND METHODS OF MAKING AND USING THE SAME | TRUSTEES OF TUFTS COLLEGE (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025054426-A1 | EDIBLE TRANSFERABLE HOLOGRAPHIC IMAGE FILMS AND METHODS | TRUSTEES OF TUFTS COLLEGE (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025024809-A1 | SYSTEMS AND METHODS FOR SILK WASTE STREAM PROCESSING | TRUSTEES OF TUFTS COLLEGE (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025007132-A2 | CENTRIFUGALLY-MOLDED ARTICLES AND METHODS | TRUSTEES OF TUFTS COLLEGE (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20050214298-A1 | Neovascular-targeted immunoconjugates | YALE UNIVERSITY (US) | 2005-09-29 | — | — | US | disclosed |
| US-6924359-B1 | Neovascular-targeted immunoconjugates | YALE UNIVERSITY (US) | 2005-08-02 | — | — | US | disclosed |
| EP-0971731-B1 | SUPPRESSION OF MALIGNANCY UTILIZING RIBONUCLEOTIDE REDUCTASE R1 | GENESENSE TECHNOLOGIES INC (CA) | 2004-05-12 | — | — | EP | disclosed |
| US-20030087866-A1 | Suppression of malignancy utilizing ribonucleotide reductase R1 | GENESENSE TECHNOLOGIES INC. | 2003-05-08 | — | — | US | disclosed |
| US-6472376-B2 | GENE THERAPY | GENESENSE TECHNOLOGIES, INC. (CA) | 2002-10-29 | — | — | US | disclosed |
| US-20020004488-A1 | SUPRESSION OF MALIGNANCY UTILIZING RIBONUCLEOTIDE REDUCTASE R1 | LORUS THERAPEUTICS INC. (CA) | 2002-01-10 | — | — | US | disclosed |
| US-5985824-A | Methods and compositions for treating cystic fibrosis | GENZYME CORPORATION (US) | 1999-11-16 | — | — | US | disclosed |
| US-5834421-A | Methods and compositions for treating cystic fibrosis | GENZYME CORPORATION (US) | 1998-11-10 | — | — | US | disclosed |
| US-5750571-A | Methods and therapeutic compositions for treating cystic fibrosis | GENZYME CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| US-5674898-A | SUPPLYING MUTANT PROTEIN | GENZYME CORPORATION (US) | 1997-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448352-B2 | Beta adrenergic agonist and methods of using the same | ADRA2B, ADRB2, ADRB1 | MAOA 152/4885MAOB 66/4885MAPKAPK2 2632/4885 |
| US-20260109671-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | MAOA 702/4885MAOB 663/4885MAPKAPK2 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.